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Abstract
Background: Sub-Saharan Africa is currently enduring the heaviest global burden of diabetes and diabetes care in
such resource poor countries is far below standards. This study aims to describe the gaps in the care of Ethiopian
diabetic patients at Jimma University Specialized Hospital.
Methods: 329 diabetic patients were selected as participants in the study, aged 15 years or greater, who have
been active in follow-up for their diabetes for more than 1 year at the hospital. They were interviewed for their
demographic characters and relevant clinical profiles. Their charts were simultaneously reviewed for characters
related to diabetes and related morbidities. Descriptive statistics was used for most variables and Chi-square test,
where necessary, was used to test the association among various variables. P-value of < 0.05 was used as statistical
significance.
Results: Blood glucose determination was done for 98.5% of patients at each of the last three visits, but none ever
had glycosylated haemoglobin results. The mean fasting blood sugar (FBS) level was 171.7 ± 63.6 mg/dl and 73.1%
of patients had mean FBS levels above 130 mg/dl. Over 44% of patients have already been diagnosed to be
hypertensive and 64.1% had mean systolic BP of > 130 and/or diastolic > 80 mmHg over the last three visits.
Diabetes eye and neurologic evaluations were ever done for 42.9% and 9.4% of patients respectively. About 66%
had urine test for albumin, but only 28.2% had renal function testing over the last 5 years. The rates for lipid test,
electrocardiography, echocardiography, or ultrasound of the kidneys during the same time were < 5% for each.
Diabetic neuropathy (25.0%) and retinopathy (23.1%) were the most common chronic complications documented
among those evaluated for complications.
Conclusions: The overall aspects of diabetes care at the hospital were far below any recommended standards.
Hence, urgent action to improve care for patients with diabetes is mandatory. Future studies examining patterns
and prevalence of chronic complications using appropriate parameters is strongly recommended to see the true
burden of diabetes.
Background
Diabetes mellitus (DM) is one of the chronic illnesses
with multi-system complications; the prevalence of
which is alarmingly increasing [1,2]. It is often accompa-
nied by various chronic complications that may affect
the productivity and quality of life inevitably [3]. Today,
at least in the western world, DM is the leading cause of
blindness; non-traumatic amputation; and chronic renal
failure [4]. Diabetes reduces life expectancy by 5 to 10
years. Premature cardiovascular disease is the most
common cause of mortality [5].
The duration of diabetes, degree of hyperglycaemia,
hypertension, dyslipidaemia, and smoking are the stron-
gest risk factors for chronic complications of diabetes
[5]. The risk of vascular complications can thus be
greatly reduced by tight management of these risk fac-
tors [5-8]. In fact, diabetes care is complex and requires
continuing medical care and patient self-management
education [6]. * Correspondence: esakgd@gmail.com
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Indeed, coronary heart disease is already the leading
cause of mortality in some developing countries [10]. In
s u b - S a h a r a nA f r i c ai np a r t i cular, the condition is even
worse due to late diagnosis and poor access to diabetes
care [9-12].
Diabetes is not uncommon in Ethiopia but the inci-
dence and prevalence of the disease is not well known
in the community. Limited studies have shown a signifi-
cant increase in its prevalence over the last four decades
[13-17], poor access to diabetes care [18], and high rates
of chronic complications [19-26]. In one of the recent
studies, accesses for blood glucose monitoring and dia-
betes health education were found to be very low.
A b o u th a l fo ft h ep a t i e n t sd i d n ’t have urine analysis,
renal function and lipid test done in the previous 1-2
years and none ever had glycosylated haemoglobin
(HbA1c) determination. About 75% of the patients
required admissions directly or indirectly due to uncon-
trolled diabetes [18]. The cost of inpatient diabetes man-
agement in the country is enormous being significantly
higher than the cost of other inpatient managements
[27].
However, diabetes in Ethiopia has never been given
the attention it deserves. Glycaemic control and man-
agement of co-morbid conditions and diabetes compli-
cations are alarmingly sub-optimal and perhaps one of
the worst in the world [18]. Furthermore, the overall
disease burden in the country is unknown due to very
limited studies in the country. The available studies lack
generalizability due to small sample sizes most of which
were limited to the capital, Addis Ababa. Besides, there
is no national strategy for the prevention and control of
diabetes.
T h ea i mo ft h i ss t u d yw a st od e s c r i b et h ec u r r e n t
situation for a group of Ethiopian diabetic patients
regarding diabetes specific characteristics, assessment of




a cross-sectional study design was used.
Settings
This study was conducted from August 29 to November
2, 2009 at Jimma University Specialized Hospital
(JUSH). JUSH is a teaching and referral hospital located
in Jimma town, Southwest Ethiopia. Diabetes clinic is
one of the many chronic follow-up clinics of the hospi-
tal occurring twice weekly on Mondays and Tuesdays.
The service is rendered by internists, medical residents,
medical interns, and general nurses (with no special
training).
Frequency of follow-up visits is at least 3 times a year
and depends on proximity to hospital and need for close
follow-up. Patients with evidence of complications get
more frequent check-ups. On each visits, patients are
usually given diabetes health education by members of
Ethiopian Diabetes Society, who are non-professionals
and have diabetes themselves. On the follow-up day, all
patients are expected to come with results of FBS done
within 48 hours. Their charts are kept at diabetes fol-
low-up clinic.
Participants of this study were diabetic patients who
have been active in follow-up for their diabetes for more
t h a n1y e a ra tJ U S H .A tt h et i m eo ft h es t u d yt h e r e
were a total of 1716 diabetic patients (both adult and
paediatric patients) on follow-up care at the hospital. Of
these, 1353 were older than 15 years and were taken as
a target population from which study participants were
selected.
Selection of study participants
a sample size of 329 patients was obtained using a mini-
mum sample size calculation. All eligible patients who
were willing to participate in the study were scrutinized
until the planned sample size was obtained. They were
invited to participate in the study in consecutive order
and their records were reviewed after their consents
were obtained. For those who had repeated clinic visits
during the study period, data were collected during their
first visits. For the 19 patients who declined to partici-
pate in the study, no further information was obtained
from them or their records.
Data collection
The data were collected by using a structured question-
naire which was specifically prepared for this study and
was compared with those used in previous studies done
in the country. Patients were interviewed for their
demographic features, characters related to diabetes and
hypertension management where applicable, hospital
admission, current symptoms, and their attitude towards
care given to them. Their charts were reviewed for types
of diabetes; types of treatments for diabetes and hyper-
tension; last three records of blood glucose, BP, and
weight; and causes of admission. Documented findings
of laboratory data, ECG, imaging studies, eye evalua-
tions, neurologic examinations, and diabetes complica-
tions were also sought from their medical records.
Patients were interviewed in a separate room with com-
plete privacy. Both the interviews and record reviews
were done by medical interns and residents.
Data quality control
to ensure the quality of data, data collectors were
selected based on their interests and were adequately
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investigators. Information provided by patients for doses
of drugs, treatment modifications, and clinical evalua-
tions were cross checked from their records for consis-
tency. The collected data were also checked for
completeness and internal consistency.
Data processing, analysis and interpretation
the data were coded, cleaned, entered and analysed with
the help of SPSS window program version 16. Descrip-
tive statistics was used for most variables and Chi-
square test, where necessary, was used to test the asso-
ciation among various variables. P-value of < 0.05 was
used as statistical significance. Average blood sugar,
blood pressure and weight refer to the average of the
last three measures.
Ethical considerations
Ethical approval was obtained from Jimma University
Ethical review board. Informed and written consent was
obtained from each study participant. People with life




The male to female ratio was 1.46:1. The mean age of
patients at the time of the study was 48.4 ± 15.1 years
with range of 15 to 82. The duration since DM diagno-
sis ranged between 1 and 41 years with a mean of 7.4 ±
5.2 years. Family history of DM was reported by a fifth
of patients, with the proportion being higher among
type 2 patients (Table 1).
Adequacy of glycaemic control
Blood glucose was measured for 98.5% of the patients
during all of their last 3 visits. None of the patients ever
had glycosylated haemoglobin test (Table 1). The aver-
age FBS was comparable among both types of diabetes
with mean of 171.7 ± 63.6 mg/dl. Over 2/3
rd of both
groups had a mean FBS above the target level of 130
mg/dl (Table 2).
Except for 1 patient, all were on pharmacologic ther-
apy for their diabetes at the time of study. The delay in
pharmacologic treatment after diagnosis was about 3
months and was longer in type 2 patients, 1 and 4
months for type 1 and 2 respectively(p < 0.01). At the
time of the study, more than half of the patients were
taking insulin alone or in combination with OGLA. The
mean daily dose of glibenclamide was high with 54.0%
of the patients taking at least 20 mg daily (Table 2).
Patients taking a single OGLA alone had a better glu-
cose levels than those taking insulin alone or combina-
tion of OGLAs or insulin and OGLA (p = 0.0006).
Patients taking lower doses of oral agents also had bet-
ter blood sugar control than those taking higher doses.
However, a similar trend did not occur for insulin.
Among patients taking combination OGLA, 56.6% were
taking glibenclamide ≥20 mg/d and metformin ≥1000
mg/d and over 90% of them had sub-optimal glycaemic
control. Despite having FBS well above target level over
the last three visits, no modification was done for
Table 1 Background characteristic of diabetic patients on
follow-up at JUSH, November 2009
Characteristics Frequency %
Age (years)
15 - 34 62 18.8
35 - 64 212 64.4











Non-formal education 14 4.3
Elementary 105 31.9
High school 57 17.3
Above high school 41 12.5
Type of diabetes
Type 1 117 35.6
Type 2 212 64.4
Family history of diabetes
Yes 67 20.4
No 262 79.6
Duration since diagnosis (years)
1-5 157 47.7
6-10 106 32.2
≥ 11 66 20.1
Blood glucose on each visits









RBS - random blood sugar, SMBG - self monitoring of blood glucose, FBS -
fasting blood sugar
*One patient was not taking any glucose lowering agent and was not
included.
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(Table 3).
Level of glycaemic control was not significantly
affected by sociodemographic characteristics of the
patient, duration of diabetes, health education, and fre-
quency of visits.
Assessment of Adequacy of Hypertension management
The mean BP over the last three visits was 124.1 ± 17.2
and 80.7 ± 9.4 mmHg for SBP and DBP respectively. At
the time of the study, 44.4% of patients had already
been diagnosed to have hypertension. The majority
(89.0%) of them were on pharmacologic treatments. The
commonly used antihypertensive drugs were ACE inhi-
bitors. About 75% of them were taking a single antihy-
pertensive agent (Table 4).
Only 6.8% of patients already diagnosed to have
hypertension had target BP level of <130/80 mmHg.
Among patients who have never been diagnosed to have
hypertension, 41.0% (75/183) had measurements higher
than the target. Overall, 64.1% of the patients had BP
higher than the target level at least over the last three
visits. Despite having higher BP over the last three visits,
only 21.8% of these patients had modification of their
antihypertensive treatment (Table 5).
Assessment of efforts done to watch for and prevent
diabetes related morbidities
Only 68.1% of the patients had their weight measured
on each visits of the last 3 with mean of 64.4 ± 12.1 Kg
(59.3 ± 10.8 kg in type 1 and 67.1 ± 11.9 kg in type 2).
No patient had his BMI ever done as there is no routine
height measurement at the clinic (Table 6).
Diabetes eye evaluations (visual acuity and ophthalmo-
scopic examination) were done for only 42.9%. Of them
only 35.5% were sent as part of routine evaluation. Dia-
betic retinopathy was documented in 18.4% of them.
Among 31 for whom neurologic examination was done,
28 (90.3%) had evidence of sensory polyneuropathy
(Tables 6).
Only 29.5% (97) of the patients had renal function test
(RFT) done over the last 5 years, 19.8% (19) of them
had impaired renal function. Urinalysis was done for
65.7% of patients. The rates of proteinuria, glycosuria,
and ketonuria were 28.7, 63.4, and 9.3% respectively
(Table 6).
Over 10% of patients reported hospital admission over
the past year due to diabetes related conditions. Dia-
betes related complications were documented in 32.8%
of the patients. About 75% of them were complaining of
DM related symptoms at the time of study (Table 6).
Table 2 Patterns of glycaemic management among diabetic patients at JUSH, November 2009
Glycemic managements Type 1 DM Type 2 DM Total
N%N%N%
Initial management
MNT 4 3.4 14 6.6 18 5.5
OGLA 15 12.8 188 88.7 203 61.7
Insulin 98 83.8 9 4.2 107 32.5
Herbal treatment 0 0.0 1 0.5 1 0.3
Current management
MNT alone 0 0 1 0.5 1 0.3
Insulin alone 109 93.2 61 28.8 170 51.7
Insulin and OGLA 7 6.0 6 2.8 13 4.0
Single OGLA 0 0.0 69 32.5 69 21.0
Combination OGLA 1 0.8 75 35.4 76 23.1
Initiation of pharmacologic treatment
At the time of diagnosis 112 95.7 184 86.8 296 90.0
Later on 5 4.3 28 13.2 33 10.0
FBS (mg/dl)
< 70 0 0.0 2 1.0 2 0.6
70-130 24 22.4 58 28.3 82 26.3
> 130 83 77.6 145 70.7 228 73.1
Doses of drugs (mean ± SD)
Insuline - IU 52.4 ± 20.1 45.0 ± 15.8 49.7 ± 19.0
Glibenclamide - mg/dl 20.0 ± 0 15.2 ± 6.5 15.3 ± 6.5
Metformine- mg/dl 625.0 ± 231.5 882.0 ± 406.1 860.8 ± 400.1
MNT - medical nutritional therapy, OGLA -oral glucose lowering agent, FBS - fasting blood sugar
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Despite all the above findings, 95.3% (313) of the
patients reported that they are satisfied with the care
they are given at diabetic clinic of JUSH.
Discussions
This study assessed a wide scope of diabetes care at
Jimma University Specialized Hospital in Ethiopia using
information from chart reviews and patients. Glycaemic
control and blood pressure control were far below any
recommended standards and attempts to prevent, detect
early and manage chronic complications of diabetes
were alarmingly poor. The mean FBS of 171.1 ± 63.6
mg/dl is better than the 190 ± 89.6 mg/dl in Addis
Ababa [18] however; it is far higher than the recommen-
dations in the developed world [6,28]. The majority of
patients (73.1%) had FBS above the target level of 130
mg/dl as compared with 79% having >120 mg/dl in pre-
vious study [18] indicating that glycaemic control in
Ethiopia is in dire need of being addressed. Similar to
most studies in the country [18], no patient had HbA1c
determination in this study because it is not available in
public health sector in the country.
Over 99% of the patients were on pharmacologic
treatment for their diabetes at the time of study with
the delay after diagnosis for drug treatment being 3
months. Reasons may be lack of routine medical check-
up and lack of knowledge of diabetic symptoms which
resulted in patients presenting only when they were
overtly sick.
Over 55% of the patients needed insulin and about
33% of type 2 patients have become insulin requiring
during the course of their diabetes. This can be
explained by the secondary insulin failure as the disease
progresses since most patients were over 5 years post
diagnosis. A similar trend has been documented in UK
Prospective Diabetes Study (UKPDS) 33 in which case a
significant proportion of patients on sulfonylurea subse-
quently required insulin due to severe hyperglycemia
[7]. The daily insulin requirement was significantly
higher in type 1 patients (52.4 Vs 45.0IU/Kg/d, p =
0.0001) which can be explained by the pathophysiology
of the disease.
Patients taking a single oral agent were found to have
a better glycaemic control than those taking insulin or
combination OGLAs (p = 0.002). Possible explanation
for this is the duration since diagnosis of diabetes as
72.5% patients taking single OGLA had diabetes for less
than 5 years. In contrast, over 60% of patients requiring
insulin and 56.6% of patients taking combination
OGLAs had DM for over 5 years. This implies that
good control in the single OGLA was due to the early
Table 3 Adequacy of glycaemic management in diabetic patients on follow-up at JUSH, November 2009
FBS
Treatment categories Average FBS, mg/dl ≤ 130 mg/dl > 130 mg/dl P-value
N%N%
Pharmacotherapeutic options
Insulin alone 170.8 37 23.6 120 76.4
Insulin and OGLA 190.3 3 23.1 10 76.9 0.0006
One OGLA 152.7 28 41.8 39 58.2
Both OGLA 188.7 15 22.4 59 77.6
Doses of drugs
Insulin
< 1IU/Kg/d 167.7 36 25.5 105 74.5 0.175
≥ 1IU/kg/d 194.5 4 13.8 25 86.2
Glibenclamide (G)
< 20 mg/d 149.4 30 50.0 30 50.0 0.0001
≥ 20 mg/d 190.0 11 15.1 62 84.9
Metformin(M)
< 1000 mg/d 163.1 15 38.5 24 61.5 0.001
≥ 1000 mg/d 204.3 5 8.9 52 91.1
Glibenclamide + metformin
G < 20 mg/d or M < 1000 mg/d 168.1 12 36.4 21 63.6 0.005
G ≥ 20 mg/d & M ≥ 1000 mg/d 203.3 4 9.5 38 90.5
Modification of glycaemic treatment during the last 3 visits
Yes 16
* 19.0 70 30.7
No 68 81.0 158 69.3
* In 13 of these patients treatment modification was for low FBS or symptoms of hypoglycemia.
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good illustration for this hypothesis is UKPDS 33 find-
ing which showed progressive increments in fasting
plasma glucose levels and doses of insulin and OGLA.
During the follow-up period in that study, the median
insulin dose increased by about 64% from 22IU at 3
years to 36IU at 12 years [7].
Similarly, patients taking lower doses of oral agents
had a far better FBS level than those taking higher
doses. More than 90% of patients taking glibenclamide >
20 mg/d and metformin > 1000 mg/d had persistently
high FBS over the last 3+ visits. The mean FBS for them
Table 4 Patterns of Hypertension management in





Pharmacologic treatment for hypertension
Yes 130 89.0
No 16 11.0
Proportion with hypertension by diabetes type
Type 1 (N = 117) 30 20.5
Type 2 (N = 212) 116 79.5
BP in mmHg
< 130/80 118 35.9
130/80 to < 140/90 110 33.4
140/90 to < 160/100 81 24.6
≥ 160/100 20 6.1
Antihypertensive agents
HCT 16 12.3
ACE inhibitor 110 84.6
Beta blocker 10 7.7
Calcium channel blocker 21 16.2
Others 11 8.4
Option of drugs
Single agent 95 73.1
Two drugs 32 24.6
Three drugs 3 2.3
BP - blood pressure, HCT - hydrochlorothiazide, ACE - angiotensin converting
enzyme
Table 5 Adequacy of Hypertension management in










Yes 10 6.8 136 93.2 0.0001
No 108 59.0 75 41.0
Pharmacologic treatment of
hypertension
Yes 9 6.9 121 93.1 0.92
No 109 54.8 90 45.2
Treatment modification of the last 3
visits
Yes 3 2.5 46 21.8 0.599
No 115 97.5 165 78.2




Weight measurements during the last 3 visits 224 68.1
Evaluation for DM neuropathy 31 9.4
Diabetic eye evaluation ever 141 42.9
Recent finding of eye evaluation
Normal 36 25.5
Cataract/glaucoma 14 9.9
Diabetic retinopathy 26 18.4
No documentation 65 46.1
Investigation over the last 5 years
RFT 97 29.5
Urinalysis 216 65.6
Lipid profile 16 4.9
ECG 13 4.0
Echocardiography 9 2.7
Ultrasound of the kidneys 13 4.0
Treatments to prevent complications
Aspirin 46 14.0
Lipid lowering drugs 9 2.7
DM related admissions during the last year 39 10.9
DKA 28 71.8
Hypoglycemia 2 5.1
Ulcer or gangrene of extremities 5 12.8
Stroke 2 5.1
Other 2 5.1
Documented complications 108 32.8
DKA 44 40.7
Peripheral neuropathy 27 25.0
Diabetic retinopathy 25 23.1
Diabetic foot ulcer 11 10.2
Stroke/IHD 12 11.1
Others 7 6.5
Current symptoms 247 75.1
Blurring of vision 106 32.2
Numbness 100 30.4
Polysymptoms 74 22.5
Easy fatigability 71 21.6
Breathlessness/Chest pain/Body swelling 51 15.5
Foot ulcer/delayed wound healing 22 6.7
Impotence 15 4.6
Others 21 6.4
RFT - renal function test, ECG - electrocardiography, DKA - diabetic
ketoacidosis, IHD - ischemic heart disease
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sis for over 5 years. Surprisingly, over 80% of them did
not have any modification in their glycaemic manage-
ment over the last three visits. It is probably important
here that patients taking such a high dose of oral agents
a r en om o r er e s p o n s i v et ot h e ma n dm a ys o o n e rn e e d
insulin therapy [7]. Overall, a high FBS over the last 3
visits did not attract attention of treating physicians. In
about 70% of the patients with high blood sugar, no
modification in treatment regimen was done. Possible
reasons are lack of awareness, time constraint, lack of
adequate human power, and most importantly lack of
appropriate guidelines and diabetes education for both
care givers and patients.
Access for SMBG remains to be very low as it has
been in previous study [18] (5.5 vs. 5.0%). However,
access for blood glucose determination at the hospital
was not found as a constraint as 98.5% of the patients
had it done during each of the last three visits. Blood
glucose determination is free at the hospital, but
patients need to buy the glucometer and the strips for
SMBG.
Morbidities and mortalities in patients having coexis-
tence of hypertension and DM are immense [29,30].
Due to this fact, the target BP level for diabetes is con-
sistently dropping and has become lower than the target
l e v e lo ft h eg e n e r a lp o p u l a t i o n[ 6 ] .I np r e v i o u ss t u d i e s
in Ethiopia, hypertension was found to be an associated
morbidity in 19.9% of diabetic patients as in Lester FT
1988 [31] and 34% Feleke Y 2005 [18]. However, the
proportion of patients with hypertension in this study is
much higher than the national findings and figures in
the western world [29,30]. In this study, 44% patients
have already been diagnosed with hypertension at the
time of the study. Overall, 64.1% of the patients had sys-
tolic BP ≥130 mmHg and/or diastolic≥80 mmHg, and
24.6% had >140 and/or ≥ 90 mmHg.
About 90% of patients diagnosed to have hypertension
were on pharmacologic therapy, the majority of which
were taking ACE inhibitors, which abides with the gen-
eral recommendation [6,32]. However, only 6.9% of
patients currently taking antihypertensive medications
had target BP. This figure, which does not look better
than placebo effect, might have been due to under
dosage, poor adherence to medications and lifestyle
management, and less concern by health care providers.
The same as in the glycemic management, even
though 100% of the patients had BP measurement on
each visits; it was rarely used for patient management.
Among patients not considered to have hypertension,
41.0% had mean BP of hypertensive ranges over the last
3 visits. Despite having BP of hypertensive range over
the last three visits, 79.2% of the patients did not have
modification to their hypertension regimen.
The proportion of patients who have been evaluated
for diabetes related morbidities is very low. Less than
30% had RFT done and about 35% of patients did not
have urinalysis within the last 5 years. Less than 5% of
the patients had ECG, echocardiography, lipid test, or
ultrasound of the kidneys. Alarmingly a significant pro-
portion of tested patients had abnormal findings. Most
of the imaging studies would have been expensive and
inaccessible in the hospital setting; however, urine dip-
stick for albumin test is cheap and readily available at
the hospital.
Far from recommended practice less than 10% of
patients had ever had an evaluation for diabetic neuro-
pathy. Those who had been examined were those with
disabling symptoms as 90.3% of those evaluated had evi-
dences for peripheral sensory polyneuropathy. Similarly,
only 42.9% of patients in this study ever had a recom-
mended yearly eye evaluation and the majority were
evaluated for their symptoms rather than as a routine
screening follow-up.
Diabetic ketoacidosis was found to be the commonest
cause of hospital admission. Peripheral neuropathy and
retinopathy were the most typical chronic complications
identified. These findings are compatible with previous
studies in Ethiopia [19] and other countries in Africa
[22-26]. Similarly, the chief complaints for most patients
were eye and sensory related. A significant proportion
of them also had polysymptoms of diabetes that indi-
cates poor sugar control.
Lifestyle management is an important component of
diabetic care [6] and intensive nutrition treatment
besides the conventional pharmacotherapy has been
shown to improve both glycaemic control and anthro-
pometric measures [33]. In this regard, diabetes nurse
educators and diabetes dietitian play an important role
in diabetic care. However, no emphasis has been given
to diabetes health education at the clinic and in Ethio-
pia in general. To date there are no diabetes nurse
educators and diabetes dietitian in the country. Those
rendering health service for diabetes patients at the
hospital had no special training for diabetes care and
most of them were medical interns who were naïve
not only to diabetes care but also to the general medi-
cal practice.
Demographic backgrounds, type and duration of DM
since diagnosis, and duration of pharmacologic treat-
ment of hyperglycemia were not found to affect level of
glycaemic control. Similarly, the influences of good gly-
cemic and hypertension control on morbidity were not
observed in this study probably due to two major rea-
sons. Firstly, most of the patients did not have adequate
glycaemic and BP control. Secondly, documentation for
diabetes related morbidities was found for only 1/3
rd of
patients.
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system and widespread trend of not documenting physi-
cal findings, laboratory results, and reason for changing
managements. Despite this, the majority of the patients
reported that they were satisfied with the care they were
given at the clinic indicating that patients have inap-
propriate expectation about diabetes care. Poor aware-
ness among patients about the extent and components of
diabetes care affects not only their expectations but
importantly the quality of services they obtain and the
outcome of diabetes. In this study it may be mentioned
here that patients might have been satisfied with the free
laboratory services (for blood glucose) and medications,
which were probably their main expectations of the care.
The strengths of our study was the high patient
response rate, good cooperation from hospital staff, and
the fact that it was one of the few studies on diabetes
care in Ethiopia.
There are potential shortcomings in our study that
require comment. The major limitation was poor chart
keeping that might have limited us from getting full
information about chronic complications of diabetes.
Another limitation was the cross-sectional study design
that is not adequate to assess most of the chronic com-
plications of diabetes. The classification of diabetes to
type 1 and type 2 was based solely on history and age of
the patient. In this study, the proportion of type1 was
35.6% which is much higher than findings in the wes-
tern world of 5 -10% [6]. We thus think that the pro-
portion of type 1 diabetes may be lower than our
finding with appropriate antibody study.
Conclusions
Glycaemic and hypertension controls in diabetic patients
at JUSH were far below any recommended standards and
attempts to prevent, detect early, and manage chronic
complications of diabetes were alarmingly poor. Besides
these, inadequate knowledge and perception of patients
about the scope of diabetic management and trends of
poor documentation at the clinic were major constraints
identified affecting over all care of diabetes patients.
Thus, we strongly recommend that urgent action
should be taken to improve the management of such an
alarmingly increasing morbidity that, if not acted upon,
is debilitating to the patient and heavy burden to the
economy of the country in particular. Due emphasis
should be given to clinical examination and urine albu-
min test to screen for chronic complications of diabetes
which are highly cost effective in such resource con-
straint settings. Available information should also be
carefully interpreted and the findings be acted upon
timely and appropriately. The documentation systems
not only for diabetic patients but also for the general
medical practice should improve so that patients will
obtain an optimum and timely care. Further clinical
investigations for adequacy of diabetes care and diabetes
complications with appropriate parameters are also
warmly recommended.
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